Compare TBPH & VINP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TBPH | VINP |
|---|---|---|
| Founded | 2013 | 2009 |
| Country | United States | Brazil |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 824.9M | 702.6M |
| IPO Year | 2013 | 2020 |
| Metric | TBPH | VINP |
|---|---|---|
| Price | $16.45 | $10.55 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 2 |
| Target Price | ★ $18.40 | $14.00 |
| AVG Volume (30 Days) | ★ 528.6K | 73.3K |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | N/A | ★ 5.92% |
| EPS Growth | ★ 279.13 | N/A |
| EPS | ★ 2.06 | N/A |
| Revenue | ★ $15,386,000.00 | N/A |
| Revenue This Year | $1.04 | $20.11 |
| Revenue Next Year | N/A | $16.18 |
| P/E Ratio | ★ $8.05 | $24.41 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $8.12 | $8.92 |
| 52 Week High | $21.03 | $13.61 |
| Indicator | TBPH | VINP |
|---|---|---|
| Relative Strength Index (RSI) | 58.98 | 41.83 |
| Support Level | $13.41 | $9.35 |
| Resistance Level | $19.04 | $10.87 |
| Average True Range (ATR) | 0.53 | 0.45 |
| MACD | 0.37 | 0.10 |
| Stochastic Oscillator | 99.04 | 69.55 |
Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.
Vinci Compass Investments Ltd is an alternative investment platform in Brazil. Its business segments include Private Equity, Equities, Real Assets, Credit, Global IP&S, and Corporate Advisory. The company's majority of its revenue comes from the Private Equity segment, which is comprised of five business lines: private equity, real estate, infrastructure, credit, and special situations.